Cetyl Myristoleate Functions Cetyl Myristoleate (CMO) seems to function in at least four different ways. One of the
first observations noted when favorable CMO results are seen is the lubricating
quality of
Cetyl Myristoleate (CMO). Decrease or loss of morning stiffness is
commonly noted shortly after commencing CMO treatment. Next,
Cetyl Myristoleate
functions as an anti-inflammatory. Lessening of swollen digits is often seen after
the 4th or 5th week of Cetyl Myristoleate treatment. Third,
Cetyl Myristoleate
CMO functions as an immunomodulator or immune system regulator.
Cetyl Myristoleate’s
ability to regulate or calm down hyper-immune responses is one of the most exciting
qualities and shows that CMO may be helpful in addressing the symptoms related
to many autoimmune diseases. And finally,
Cetyl Myristoleate functions as an analgesic
or painkiller and CMO has been helpful for many sufferers of muscle tension headaches
and fibromyalgia.
An Update on Cetyl Myristoleate (CMO) Chuck Cochran,
D.C. I can’t believe it,
but it’s been over four years since I first wrote a small booklet entitled Dr.
Chuck Cochran Discusses Arthritis & Cetyl Myristoleate. As you can imagine
a lot has transpired since that time. We now have quite a few healthcare practitioners
who use Cetyl Myristoleate (CMO) regularly in their offices and Cetyl Myristoleate
is being sold through several nutritional lines in health food stores. Several
multi-level companies now offer
Cetyl Myristoleate (CMO) and related products
in their lines, and recently,
Cetyl Myristoleate was put in a formula to treat
arthritis in dogs. Cetyl Myristoleate has also been written about in Robert Atkins’,
M.D. most recent book entitled Vita-Nutrient Solution – Nature’s Answer to Drugs.
And Sherry Rogers, M.D., for her soon-to-be-completed book on chronic pain, recently
interviewed me about
Cetyl Myristoleate. I also had the fortunate opportunity
to be interviewed by Total Health (Volume 21, No. 1). I’ve found that there’s
a big difference in all of these CMO products, however, and so I appreciate the
opportunity to share some of the information that I’ve gathered since I was first
introduced to
Cetyl Myristoleate - this marvelous molecule.
The
History of Cetyl Myristoleate For those
of you who have not heard or read about
Cetyl Myristoleate, let me give you just
a little background. The
Cetyl Myristoleate discovery occurred during a two-year
period from 1962 to 1964 by Harry W. Diehl while on a personal quest to find a
cure for arthritis. Harry was a research chemist working in sugar metabolism at
the National Institutes for Health in Bethesda, Maryland. During his time there,
over 40 years, he was responsible for isolating and identifying over 500 chemical
compounds. Many of these were patented. His most notable discovery, prior to
Cetyl Myristoleate, was a sugar used in the preparation of Dr. Jonas Salk’s oral polio
vaccination. His discovery of
Cetyl Myristoleate actually occurred in a laboratory
that he had set up in his own home. The story of how he isolated the
Cetyl Myristoleate
molecule that may one day be hailed as the most significant nutritional discovery
of the 20th century and nature’s answer to arthritis is simply wonderful. Unfortunately,
I can’t relate the entire story in this short article. Hopefully, someday someone
will write the story of this very intuitive researcher. In a nutshell, this is
what Harry’s research revealed:
Mice are immune to arthritis.
The molecule that provides this
immunity is Cetyl Myristoleate (the cetyl alcohol ester of the 14 carbon chain
fatty acid myristoleic acid).
Cetyl
Myristoleate circulates in the bloodstream of mice at approximately 350 mg / kg
bodyweight and with proper doses of Cetyl Myristoleate extracted from mice (450
–500 mg / kg body weight), he could provide rats with 100% immunity to adjuvant-induced
arthritis.
After injecting
the Cetyl Myristoleate into the rats, the highest concentrations were found in
the liver.
Harry developed
a way of synthesizing Cetyl Myristoleate by combining cetyl alcohol with myristoleic
acid and found that the synthesized form of
Cetyl Myristoleate was just as effective
in providing rats immunity to adjuvant-induced arthritis as the naturally occurring
form (extracted from mice).
Subsequent CMO
Research A more recent
Cetyl Myristoleate
study, performed by H. Siemandi, M.D., Ph.D., was published in the August / September
1997 issue of the Townsend Letter for Doctors & Patients. This
Cetyl Myristoleate
study was performed as a randomized, double blind, placebo parallel trial with
382 patients who had been diagnosed with degenerative joint disease (DJD or osteoarthritis),
rheumatoid arthritis, and psoriatic arthritis. This group was divided into three
groups for testing. The first Group A received
a complex of fatty acids (90 grams) containing 12% Cetyl Myristoleate, the second
Group B received the same complex of CMO
fatty acid esters plus glucosamine hydrochloride, sea cucumber (a sea animal commonly
found in the Great Barrier Reef in Australia – related to the Starfish), and hydrolyzed
cartilage, and the third Group C received
a placebo. Treatment consisted of a one-month protocol. Outcome measures included
a variety of patient-reported, clinical, laboratory, and radiographic assessments.
The results were as follows (expressed in percent improvement):
Group A
Group B
Group C
Treatment Response
63.3%
87.3%
14.5%
M.D. Overall Assessment
58.1%
84.2%
13.9%
Patient Overall Assessment
59.2%
88.2%
16.1%
Joint Swelling Score
47.5%
77.2%
21.1%
Mechanisms
of CMO Action and Indications The exact
mechanisms of
Cetyl Myristoleate action are not fully understood. Several theories
have been presented, but as of today, there has been no research in this regard.
Being a fatty acid ester, one mechanism being presented is that
Cetyl Myristoleate
somehow manipulates the production of the favorable prostaglandins, (series 1
and/or 3) and leukotrienes over the unfavorable prostaglandins of the 2nd series
and pro-inflammatory leukotrienes. Prostaglandins and leukotrienes are unsaturated
fatty acids that regulate many local metabolic processes including inflammation,
platelet aggregation, pain, fluid balance, and nerve transmission. These effects
could be accomplished by inhibition of the arachidonic acid cascade and the cyclo-oxygenase
and lipoxygenase pathways.
Another mechanism being discussed is that these CMO fatty acid esters are somehow
incorporated into the phospholipid cell membranes and alter cell membrane permeability
and receptor sites. This could explain the possible theory of altering T-lymphocyte
function during the hyper-immune response related to autoimmune diseases. Although
the mechanisms are unknown, we can clinically observe
Cetyl Myristoleate’s effects.
Cetyl Myristoleate seems to function in at least four different ways. One of the first
observations noted when favorable results are seen is the lubricating quality
of Cetyl Myristoleate. Decrease or loss of morning stiffness is commonly noted
shortly after commencing CMO treatment. Next, Cetyl Myristoleate functions as
an anti-inflammatory. Lessening of swollen digits is often seen after the 4th
or 5th week of Cetyl Myristoleate treatment. Third, Cetyl Myristoleate functions
as an immunomodulator or immune system regulator.
Cetyl Myristoleate’s ability
to regulate or calm down hyper-immune responses is one of the most exciting qualities
and shows that Cetyl Myristoleate may be helpful in addressing the symptoms related
to many autoimmune diseases. And finally,
Cetyl Myristoleate functions as an analgesic
or painkiller and CMO has been helpful for many sufferers of muscle tension headaches
and fibromyalgia.
Recommended CMO Dose
We have found that many of those individuals who have taken
Cetyl Myristoleate
(CMO), and have not responded, have often taken doses far below what is recommended.
Results are related to the quality of the product as well as the amount of
Cetyl Myristoleate taken orally (therapeutic or loading dose). If we do a little mathematics,
and use the amount of CMO circulating in the bloodstream of mice as a comparison
(350 mg / kg), we conclude that a 160-pound person could require up to 24.5 grams
CMO. Fortunately, possibly because human and mouse metabolism differ greatly,
we have found that doses of 12 grams to 18 grams of elemental Cetyl Myristoleate
as a therapeutic or loading dose taken over a three to four week period of time
works fantastically well. However, there are those individuals that require a
second CMO protocol. And once the desired results have been achieved, there are
many individuals that benefit from taking much smaller, perhaps daily, CMO maintenance
doses.
Concerning the quality, there
is a wide degree of very diverse Cetyl Myristoleate products available today.
In fact, some of the CMO formulas have no
Cetyl Myristoleate in them at all! Before
purchasing any of these formulas, please read the label to determine exactly how
much Cetyl Myristoleate is available. It is imperative that the formula contains
a minimum of 12% CMO levels. If the levels are below this amount, you’ll probably
have to take a wheelbarrow full before seeing any results! In other words (let’s
do a little math), if you’re trying to achieve a therapeutic dose of 12 grams
of CMO and the CMO levels are at 12%, you will need a total of 100 grams of mixed
fatty acid esters in this particular CMO formula. If the CMO levels are at 20%,
you will need a total of only 60 grams. If the manufacturer has not listed the
percentages and the total amount of fatty acid ester complex, I would be very
hesitant in purchasing that particular product. Without this information, you
have no way of determining how much you need to take, for how long, and what would
be a good maintenance dose.
There are many different
Cetyl Myristoleate
and related products available today. There are several which, either through
ignorance or unethical marketing, have contributed to extensive confusion in the
nutritional and healthcare industry. There are several issues that I’d like to
address in this regard. First, Cetyl Myristoleate (CMO) is not CMOTM. CMOTM is
a trademarked product that is being sold as cerasomal cis-9 cetyl myristoleate,
an analog of cetyl myristoleate. The term cerasomal (waxy body?) is not in your
chemistry texts and was constructed by the manufacturer to set his product apart.
The term analog is defined as a similarly structured molecule. In other words,
CMOTM contains a similar molecule, but is not Cetyl Myristoleate. Chemical analysis
performed on several occasions, using Gas Chromatography, Mass Spectrometry, and
Flame Ionization Detection has revealed very little, if any, Cetyl Myristoleate
in this product. Unfortunately, the manufacturer, as of today, has not disclosed
exactly what his product is.
Another embarrassing mix up is that, at least,
one of the manufacturers started with a raw material that contained high levels
of myristic acid (C14:0) instead of myristoleic acid (C14:1). Myristic acid is
the saturated analog of myristoleic acid and when esterified with cetyl alcohol
produces Cetyl Myristate, not
Cetyl Myristoleate. Before the sophisticated diagnostic
procedures to analyze for CMO were developed, many of these products were analyzed
using improper or inadequate methods. These products are now on our health food
store shelves and in the MLM industry being sold as Cetyl Myristoleate, but in
fact are Cetyl Myristate. Interestingly, there have been many who have experienced
benefits from these Cetyl Myristate products. And I have found that, in one particular
formula, the Cetyl Myristate seems to enhance the effectiveness of the Cetyl Myristoleate.
They may form a true synergism.
And, finally, all
Cetyl Myristoleate products
are not created equally. Chemical analysis of several different products has revealed
that the CMO levels range from 1% up to 40%. And to add to the confusion, I have
found products that contain lower percentages of CMO (20% - 30%) that seem to
work better than the Cetyl Myristoleate products with higher levels. Please note
that there are no CMO products today that are 100% pure. With all of these products
you will find a complex of other fatty acid esters, for example cetyl stearate,
cetyl palmitate, cetyl palmitoleate, cetyl oleate, and cetyl myristate, in different
proportions. What we’re now finding is that some of these fatty acid esters may
inhibit the positive effects of the Cetyl Myristoleate, while others work with
the CMO, as I mentioned above, in a cooperative way.
For those of you technical
individuals out there, Gas Chromatography – Flame Ionization Detection (GC-FID)
analysis is now considered one of the most accurate techniques for detecting these
fatty acid esters. Here’s something that you may also find interesting. Further
analysis of the product used by Dr. Siemandi in his study showed that it actually
contained 10.8 grams of Cetyl Myristoleate, and not 18 grams, as stated in his
report. And one very current analysis of this same material indicated that the
CMO levels could have been only 9 grams delivered in a one- month protocol. It’s
truly amazing what results were achieved with only 9 or 10 grams of active ingredient!
And for those of you who are suffering with any types of aches or pains,
you and Cetyl Myristoleate deserve to get to know each other! God speed on your
road to health!
Healthier Harvest Nutrition Center
9201 Wesley Street Suite C-2
Greenville, TX 75402 1-888-834-9811
health@geusnet.com
The information contained within this website is intended for
educational purposes only. It is not intended for the treatment,
cure, diagnosis, or mitigation of a disease or condition.
Persons with potentially serious medical conditions should seek
professional care. No therapeutic or medical claims have been
implied or made.
*Product statements made have not been evaluated by
the food and Drug Administration. Products are not intended to diagnose,
treat, cure or prevent any disease.